RareMD, Inc., a privately-owned digital life sciences company focused on developing a novel web application RareMD™️ to “Find that elusive Diagnosis” today announced the appointment of Prof. Christian J. Hendriksz, M.D., M.B.C.h.B., M.Sc., F.R.C.P.C.H., as chief medical officer.
CARLSBAD, CA., Jan. 31, 2019 RareMD, Inc., a privately-owned digital life sciences company focused on developing a novel web application RareMD™️ to “Find that elusive Diagnosis” today announced the appointment of Prof. Christian J. Hendriksz, M.D., M.B.C.h.B., M.Sc., F.R.C.P.C.H., as chief medical officer. Prof. Hendriksz is a metabolic disease specialist with an extensive background in clinical therapeutic development and treatment of patients who suffer from rare genetic inborn errors of metabolism. His work has been published in more than 140 peer-reviewed publications, reviews and other clinical literature.
“We are delighted to welcome Prof. Hendriksz to the RareMD team,” said Dick H.A. Meijer, founder and Chief Executive Officer of RareMD Inc. “Chris brings tremendous clinical expertise in the field of rare and neglected diseases and will be instrumental in driving awareness of the differential diagnosis processes, the integrate use of RareMD™️ amongst frontline physicians with patients who suffer from difficult to diagnose diseases.”
Furthermore, Prof. Hendriksz will provide developmental direction for RareMD’s application and while serving as a liaison between physicians, patients and advocates so RareMD can deliver on its mission to increase awareness and education in emerging countries. Prof. Hendriksz will remain Chief Executive Officer of FYMCA Medical, Ltd.
“I share RareMD’s passion for ‘finding the elusive diagnosis’ as it aligns with FYMCA Medical’s goal to help empower patients through education,” said Prof. Hendriksz. “I am excited to join RareMD Inc., and work alongside such a talented team to expand the RareMD™️ platform and transform and expedite the diagnostic process.”
Prior to founding FYMCA Medical in 2015, Prof. Hendriksz served as a Consultant in Transitional Metabolic Medicine and clinician at the Mark Holland Metabolic Unit for Adult Inherited Metabolic Disorders based at Salford Royal NHS Foundation Trust, Manchester, UK in a part time capacity since retirement. He obtained his Bachelor of Medicine and Bachelor of Surgery (MBChB) degrees at the University of Pretoria, South Africa, in 1984. After completing his exams for Membership of the Royal Colleges of Physicians in Pediatrics in London, UK, in 1999, Prof. Hendriksz obtained a post-graduate diploma in Pediatrics and Child Health at the University of Leeds, UK, in 2001. He completed his training in Inborn Errors of Metabolism at Royal Manchester Children’s Hospital, UK. Prof. Hendriksz is a visiting Professor at the University of Pretoria, South Africa.
About RareMD Inc.
RareMD Inc. a privately-owned digital life sciences company focused on developing a novel web application RareMD™️ to “Find that elusive Diagnosis”. About 500 of the 7000 rare diseases identified by WHO are treatable with an FDA/EMA approved (orphan) drug. However, despite all R&D, clinical trials and available treatments none of these drugs or investigational orphan designated drugs (ODD) that might be approved in the near future will ever meet the unmet medical needs of tens of thousands of patients around the world if patients are not properly diagnosed in the first place.
We developed RareMD™️ to meet the unmet medical needs of about 350M people worldwide who are affected by a rare or neglected disease but remain un/misdiagnosed to date.
Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” “to end,” “to find,” or “continue,” and other similar expressions are intended to identify forward-looking statements.
RareMD Inc., undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Dick H. A. Meijer, Founder & CEO
RareMD Inc.
Dickmeijer@raremd.com
